News | Rewind Therapeutics

Rewind Therapeutics krijgt VLAIO-subsidie van 2,9 miljoen euro voor het ontdekken en ontwikkelen van nieuwe kandidaat-geneesmiddelen voor myeline-gerelateerde neurologische aandoeningen. Nieuwe industrieel-academische samenwerking maakt gebruik van belangrijke expertisegebieden in Vlaanderen en wordt gefinancierd door het Vlaamse Agentschap Innoveren en Ondernemen (VLAIO).

August 1, 2019

Rewind Therapeutics awarded €2.9 million VLAIO grant to discover and develop novel drug candidates. New industry-academic collaboration leverages key areas of expertise in Flanders and is funded by the Flanders Innovation and Entrepreneurship (VLAIO) agency for myelin-related neurological diseases

August 1, 2019

Rewind Therapeutics expands Scientific Advisory Board with addition of Professors Robin Franklin and Catherine Lubetzki, bringing further expertise in myelin and multiple sclerosis research

February 6, 2019

Rewind Therapeutics Builds Scientific Advisory Board to Accelerate Its Development of New Therapies for Myelin-Related Diseases

October 10, 2018

Rewind Therapeutics Appoints Leading Neuroscience Drug Developer Ian J. Reynolds as Chief Executive Officer

October 3, 2018

Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies

January 4, 2018

Rewind Therapeutics Secures 15.2 M EURO to Develop Novel Remyelination Therapies

January 4, 2018